ABCELLERA BIOLOGICS Total Liabilities

Latest as of June 2026: €411.56 Million EUR ≈ $481.15 Million USD

ABCELLERA BIOLOGICS total liabilities. Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has total liabilities worth €411.56 Million EUR (≈ $481.15 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are ABCELLERA BIOLOGICS's assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of ABCELLERA BIOLOGICS (2021–2025)

Total liabilities of ABCELLERA BIOLOGICS from 2021 to 2025. This chart illustrates how ABCELLERA BIOLOGICS's total liabilities have evolved over time, based on quarterly financial data. Explore 8QQ long-term investment intensity to see how much of total assets are deployed in long-term investments.

ABCELLERA BIOLOGICS Competitors by Total Liabilities

The table below lists competitors of ABCELLERA BIOLOGICS ranked by their total liabilities.

Company	Country	Total Liabilities
Zhende Medical Co Ltd SHG:603301	China	CN¥2.40 Billion
Wynn Macau Limited F:8WY	Germany	€54.06 Billion
Breville Group Ltd AU:BRG	Australia	AU$749.94 Million
China Communications Construction Company Limited F:CYY	Germany	€1.55 Trillion
Nelnet Inc NYSE:NNI	USA	$10.57 Billion
Infore Environment Technology Group Co Ltd SHE:000967	China	CN¥18.81 Billion
Hisense Kelon Electrical Holdings Co Ltd SHE:000921	China	CN¥51.29 Billion
Société Anonyme des Bains de Mer et du Cercle des Étrangers à Monaco F:RJ8	Germany	€596.51 Million

Liability Composition Analysis (2021–2025)

This chart breaks down ABCELLERA BIOLOGICS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ABCELLERA BIOLOGICS total assets.

Liquidity & Leverage Metrics

ABCELLERA BIOLOGICS Total Liabilities Ratios Explained

ABCELLERA BIOLOGICS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	12.77	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.31	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ABCELLERA BIOLOGICS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ABCELLERA BIOLOGICS (2021–2025)

The table below shows the annual total liabilities of ABCELLERA BIOLOGICS from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€390.05 Million ≈ $456.00 Million	+28.11%
2024-12-31	€304.47 Million ≈ $355.96 Million	-9.32%
2023-12-31	€335.78 Million ≈ $392.56 Million	+9.15%
2022-12-31	€307.63 Million ≈ $359.65 Million	+5.05%
2021-12-31	€292.84 Million ≈ $342.36 Million	--

About ABCELLERA BIOLOGICS

F:8QQ Germany Biotechnology

Market Cap

$4.02 Billion

€3.43 Billion EUR

Market Cap Rank

#4623 Global

#796 in Germany

Share Price

€10.60

Change (1 day)

-6.19%

52-Week Range

€2.49 - €12.80

All Time High

€44.98